Autoplaque vs ASSURE Wearable ECG

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by APQ Health (formerly Cedars-Sinai Medical Center: AIM)
VS
by Kestra Medical Technologies

AI Verdict

Autoplaque specializes in AI-powered quantitative analysis of coronary plaques and luminal stenoses from CT angiography images for risk prediction. In contrast, the ASSURE Wearable ECG is a non-therapeutic device for continuous heart rate monitoring and data collection via a wearable. While both fall under cardiology AI, Autoplaque is an imaging analysis tool, whereas ASSURE is a remote physiological monitoring system.

Choose Autoplaque if…

Choose Autoplaque if you require detailed, AI-powered quantitative analysis of coronary plaques and luminal stenoses from CT angiography images. This tool is ideal for clinicians needing precise measurements and characterization of atherosclerotic plaque to inform heart attack risk prediction and guide treatment strategies. It excels in providing in-depth anatomical and pathological insights from existing CT scan data.

View Autoplaque →

Choose ASSURE Wearable ECG if…

Choose ASSURE Wearable ECG if you need continuous, long-term heart rate monitoring and remote data collection for at-risk cardiac patients. This wearable device is best suited for detecting transient cardiac events, monitoring physiological trends, and providing alert-based notifications to clinicians through a remote patient data platform. It offers a non-invasive solution for ongoing patient surveillance outside of a clinical setting.

View ASSURE Wearable ECG →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Autoplaque ASSURE Wearable ECG
Pricing Unknown Contact for pricing.
Deployment Workstation-based post-processing application, runs on Windows or Mac OS. Wearable device, mobile application, and cloud-based remote patient data platform.
BAA Available Unknown Yes AI-estimated
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Unknown Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

ASSURE Wearable ECG

The ASSURE Wearable ECG is designed for continuous, patient-friendly use, featuring a comfortable SensorFit Garment and a mobile application for patient engagement. Kestra also provides patient training for proper use. In contrast, Autoplaque is a workstation-based software intended for trained medical professionals, requiring a specific setup and expertise for operation.

Clinical Value

Autoplaque

Autoplaque offers advanced AI-powered quantitative analysis of coronary plaques and luminal stenoses from CT angiography, providing precise diagnostic insights for heart attack risk prediction and treatment guidance. It has undergone clinical validation and significantly speeds up complex analysis with human-level accuracy. The ASSURE Wearable ECG provides valuable continuous monitoring, but Autoplaque's direct impact on detailed diagnostic assessment and treatment pathways gives it an edge in this dimension.

Pricing & Value

Tie

Both Autoplaque and ASSURE Wearable ECG have undisclosed pricing, making a direct comparison of their cost-effectiveness impossible. While some general pricing context for Kestra's related WCD system is available, specific pricing for the Wearable ECG remains opaque.

Enterprise Readiness

ASSURE Wearable ECG

The ASSURE Wearable ECG explicitly states HIPAA compliance and offers a Business Associate Agreement (BAA), critical for healthcare enterprise adoption. Its cloud-based remote patient data platform and adoption by over 550 hospitals demonstrate strong scalability and integration capabilities. Autoplaque, being workstation-based with unspecified HIPAA/BAA details, appears less geared for broad enterprise deployment.

Innovation

Tie

Both tools demonstrate significant innovation in their respective domains. Autoplaque leverages deep learning for highly specialized and rapid quantitative analysis of complex coronary plaque from CT angiography. ASSURE innovates with its patient-centric wearable design, proprietary algorithms for artifact filtering, and a comprehensive remote monitoring platform for continuous ECG data.

Support & Docs

ASSURE Wearable ECG

Kestra Medical Technologies provides explicit support channels for the ASSURE Wearable ECG, including a dedicated helpline, a Kestra Careu2122 team, and a stated three-year warranty for support services. Autoplaque's documentation mentions a user manual, but lacks specific details on ongoing customer support.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Autoplaque ASSURE Wearable ECG
Name Autoplaque ASSURE Wearable ECG
Company Cedars-Sinai Medical Center: AIM Kestra Medical Technologies
Description AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. Non-therapeutic device for continuous heart rate monitoring and data collection, integrated into their digital healthcare platform for at-risk cardiac patients.
Primary Function AI-powered quantitative analysis of atherosclerotic plaque and measurement of luminal stenoses from CT Angiographic images Continuous heart rate monitoring and automatic episode storage via a wearable ECG device
Categories Cardiology AI, Radiology & Imaging AI Cardiology AI, Wearables & Remote Monitoring (RPM)

Videos

Demos, reviews, and walkthroughs featuring Autoplaque and ASSURE Wearable ECG.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Autoplaque is an FDA-cleared AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. The ASSURE Wearable ECG is an FDA-cleared non-therapeutic device for continuous heart rate monitoring and data collection, integrated into a digital healthcare platform for at-risk cardiac patients.
Autoplaque analyzes CT angiography images to provide AI-powered quantitative data on atherosclerotic plaque, luminal stenoses, and coronary anatomy, including automated vessel, plaque, and lumen segmentation. The ASSURE Wearable ECG collects continuous heart rate data via a wearable device, offering automatic episode storage, alert-based notifications, and physiologic trend data for clinician review through the Kestra CareStation remote patient data platform.
Autoplaque uses AI for automated quantitative analysis, detection, characterization, and segmentation of coronary artery plaque and stenoses from CT images. The ASSURE Wearable ECG employs an ASSURE Detection Algorithm with Quad Channel Processing and Adaptive Patient Intelligence for filtering motion artifacts during continuous ECG monitoring.
Kestra Medical Technologies explicitly states that the ASSURE Wearable ECG is HIPAA compliant and has a BAA. For Autoplaque, information regarding HIPAA compliance and BAA is not specified in the provided details.

Backers

Who funded each tool's parent company.

ASSURE Wearable ECG

AI Tool Finder
AI-powered search. Results may not be comprehensive.